Loading…
Celldex Therapeutics, Inc. is projected to rise to $50.87 by 2027, a +32% move from its current price of $38.49. CLDX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $37.60 | $38.48 | $39.38 | -0.01% |
| Aug 2 | $37.24 | $38.48 | $39.76 | -0.01% |
| Aug 3 | $36.97 | $38.48 | $40.05 | -0.02% |
| Aug 4 | $36.74 | $38.48 | $40.30 | -0.02% |
| Aug 5 | $36.54 | $38.48 | $40.52 | -0.03% |
| Aug 6 | $36.36 | $38.47 | $40.71 | -0.03% |
| Aug 7 | $36.19 | $38.47 | $40.90 | -0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $36.19 | $38.47 | $40.90 | -0.04% |
| Week 2 | $35.27 | $38.46 | $41.93 | -0.07% |
| Week 3 | $34.58 | $38.44 | $42.74 | -0.11% |
| Week 4 | $34.01 | $38.43 | $43.43 | -0.14% |
| Week 5 | $33.51 | $38.42 | $44.04 | -0.18% |
| Week 6 | $33.06 | $38.40 | $44.61 | -0.21% |
| Week 7 | $32.66 | $38.39 | $45.13 | -0.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Celldex Therapeutics, Inc. is a healthcare biopharmaceutical company that engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. Its drug programs include Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation.
Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Celldex Therapeutics, Inc. (CLDX) is trading at $37.51 per share with a market cap of $2.94B, and is ranked 1762. The current price and market position place it among mid-cap biotechnology peers.
A major floor 25.8% below — a decisive break under it would weaken the trend.
The nearest floor, 15.7% below — buyers have tended to step in here.
The nearest ceiling, 3.8% above — a clean break opens room to run.
A major ceiling 15.5% above — clearing it would confirm fresh momentum.
Key CLDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $36.50 | Buy | $36.96 | Buy |
| MA 10 | $35.91 | Buy | $36.58 | Buy |
| MA 20 | $37.14 | Buy | $36.27 | Buy |
| MA 50 | $33.95 | Buy | $34.82 | Buy |
| MA 100 | $33.02 | Buy | $32.95 | Buy |
| MA 200 | $29.60 | Buy | $30.52 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.83 | Neutral |
| Stoch RSI (14) | 87.39 | Sell |
| CCI (20) | 57.07 | Neutral |
| Williams %R (14) | -1.06 | Info |
| MACD (12,26,9) | -0.09 | Sell |
| ROC (12) | 0.84 | Buy |
| Bollinger %B (20,2) | 0.70 | Neutral |
| Stochastic %K (14) | 98.94 | Sell |
| TRIX (15) | 0.30 | Buy |
| Awesome (5,34) | 0.77 | Buy |
| Ultimate (7,14,28) | 67.19 | Neutral |
| Momentum (10) | 3.09 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 37.34 | Buy |
| ADX (14) | 18.32 | Neutral |
| ATR (14) | 0.71 | Info |
The 30-day technical picture remains constructive, with a bullish tilt. RSI14 is 60, suggesting steady momentum, while price action sits above both the SMA50 and SMA200, which are $33.79 and $29.54 respectively.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $22.58 | $38.49 | $48.50 | 0% | Neutral | |
| $41.14 | $50.87 | $66.16 | +32% | Bullish | |
| $46.26 | $58.57 | $78.68 | +52% | Bullish | |
| $49.83 | $64.33 | $88.63 | +67% | Bullish | |
| $52.29 | $68.65 | $96.64 | +78% | Bullish | |
| $56.42 | $75.22 | $107.88 | +95% | Bullish | |
| $62.34 | $84.31 | $122.97 | +119% | Bullish | |
| $69.31 | $95.00 | $140.68 | +147% | Bullish | |
| $82.57 | $114.60 | $172.11 | +198% | Bullish | |
| $90.25 | $126.78 | $192.90 | +229% | Bullish | |
| $127.97 | $189.78 | $305.04 | +393% | Bullish | |
| $225.45 | $366.37 | $638.23 | +852% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $22.58 | $38.49 | $44.87 | +0.00% |
| August 2026 | $32.81 | $38.38 | $45.85 | -0.28% |
| September 2026 | $32.52 | $38.31 | $46.29 | -0.19% |
| October 2026 | $33.25 | $39.40 | $48.04 | +2.85% |
| November 2026 | $33.39 | $39.74 | $48.81 | +0.87% |
| December 2026 | $32.82 | $39.23 | $48.50 | -1.29% |
Click any year to see its month-by-month CLDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CLDX to range from $22.58 to $48.50 through 2026. The $38.49 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CLDX price prediction for 2027 points to an average of $50.87 (low $41.14, high $66.16) — a potential gain of +32% on today's $38.49. Buyers look set to stay in control over this stretch.
In 2028, CLDX is projected to trade between $46.26 and $78.68, averaging $58.57 — a potential gain of +52% from today's $38.49. That is up +15% on the projected 2027 average. Momentum favours further upside here.
Celldex Therapeutics, Inc.'s 2029 outlook centres on $64.33, within a $49.83 to $88.63 range. That is up +10% on the projected 2028 average. That marks a +67% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, CLDX could reach as high as $96.64, with a base case around $68.65 and support toward $52.29 — roughly +78% from $38.49. Momentum favours further upside here.
Expect CLDX to range from $56.42 to $107.88 through 2031. The $75.22 average target implies a +95% move from current prices. That is up +10% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The CLDX price prediction for 2032 points to an average of $84.31 (low $62.34, high $122.97) — a potential gain of +119% on today's $38.49. Momentum favours further upside here.
In 2033, CLDX is projected to trade between $69.31 and $140.68, averaging $95.00 — a potential gain of +147% from today's $38.49. That is up +13% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Celldex Therapeutics, Inc.'s 2034 outlook centres on $114.60, within a $82.57 to $172.11 range. That is up +21% on the projected 2033 average. That marks a +198% change versus current levels. Momentum favours further upside here.
By 2035, CLDX could reach as high as $192.90, with a base case around $126.78 and support toward $90.25 — roughly +229% from $38.49. Buyers look set to stay in control over this stretch.
Expect CLDX to range from $127.97 to $305.04 through 2040. The $189.78 average target implies a +393% move from current prices. That is up +50% on the projected 2035 average. Momentum favours further upside here.
The CLDX price prediction for 2050 points to an average of $366.37 (low $225.45, high $638.23) — a potential gain of +852% on today's $38.49. Buyers look set to stay in control over this stretch.
Investing $1,000 in CLDX today (≈ 25.98415 CLDX) could be worth
$9,519.74
+$8,519.74 (+852%) by 2050 · US Dollar
Based on the average projected CLDX price of $366.37 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLDXwould be worth at today's price.
$1,000 invested in CLDX on Jul 30, 2025 (≈ 43.840422 CLDX) would be worth
$1,687.2
+$687.2 (+68.7%) today · 1.69× · US Dollar
Based on a CLDX entry price of $22.81 vs. today's $38.49.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $35.42 | $1,086.53 | +8.7% |
| 1 month ago | $37.21 | $1,034.27 | +3.4% |
| 3 months ago | $32.31 | $1,191.12 | +19.1% |
| 6 months ago | $24.6 | $1,564.43 | +56.4% |
| 1 year ago | $22.81 | $1,687.2 | +68.7% |
| All time (5.0y) ago | $43.7 | $880.66 | -11.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLDX forecast.
Our base-case forecast reaches $77.00 around 2032.
Implied market cap at $77.00: $6.04B
The multi-year forecast shows a rising trajectory from 2026 onward. In 2026, the avg is $37.51 with a min of $22.58 and a max of $47.28 (ROI 0, sentiment NEUTRAL). By 2030, the avg shifts to $67.01 with a min of $51.01 and a max of $94.39 (ROI 78.7, sentiment BULLISH).
The forecast continues higher in 2040 (avg $185.09, ROI 393.4) and 2050 (avg $357.25, ROI 852.4), with max values reaching $297.78 in 2040 and $623.06 in 2050. These numbers point to a strong long-run upside, but they are estimates, not guarantees, and carry inherent investment risk.
Tap a question to reveal the answer.
In 2030 the forecast shows min $51.01, avg $67.01, max $94.39 with ROI 78.7 and sentiment BULLISH.
The forecast indicates a bullish trajectory across multiple years: 2027 avg $49.69 (ROI 32.5), 2028 avg $57.11 (ROI 52.3), 2029 avg $62.68 (ROI 67.1), 2030 avg $67.01 (ROI 78.7), and continuing higher through 2050 with substantial ROI. These are estimates and not guarantees.
Yes. The 2031 max is $105.22, which exceeds $100, while the 2030 max is $94.39.
RSI14 is 60 with bullish sentiment. The stock trades above the SMA50 ($33.79) and SMA200 ($29.54). Support is $32.32 and resistance is $39.93. The 30‑day range spans from $32.19 to $43.71.
The current price is $37.51 and the market cap is $2.94B.
Celldex Therapeutics, Inc. Community Discussion
0Share your Celldex Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.